We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

124 hedge funds and large institutions have $440M invested in Immunomedics Inc in 2017 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 39 increasing their positions, 32 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

140% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 15

99% more capital invested

Capital invested by funds: $221M → $440M (+$219M)

86% more call options, than puts

Call options by funds: $21.2M | Put options by funds: $11.4M

22% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 32

14% more funds holding

Funds holding: 109124 (+15)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
124
Holders Change
+15
Holders Change %
+13.76%
% of All Funds
3.07%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.07%
New
36
Increased
39
Reduced
32
Closed
15
Calls
$21.2M
Puts
$11.4M
Net Calls
+$9.85M
Net Calls Change
+$622K

IMMU Hedge Fund Activity: Q1 2017 in Review

124 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q1 2017, worth a combined $440M — up 99% from $221M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new IMMU positions and 15 closed out — a net gain of 21 holders — while 39 added to existing stakes and 32 trimmed.

The largest buyer was BlackRock, adding an estimated $40.1M. The largest seller was Acuta Capital Partners, cutting an estimated $21.3M.

  • 124 institutional investors held Immunomedics Inc (IMMU) as of Q1 2017, up from 109 in Q4 2016.
  • Funds reported $440M of Immunomedics Inc stock for Q1 2017, up 99% quarter-over-quarter.
  • 36 funds opened new Immunomedics Inc positions in Q1 2017 and 15 closed out, a net change of +21 holders.
  • The largest Immunomedics Inc buyer in Q1 2017 was BlackRock, an estimated $40.1M added.
  • The largest Immunomedics Inc seller in Q1 2017 was Acuta Capital Partners, an estimated $21.3M sold.

Based on aggregated 13F filings for Q1 2017.